An observational study in Neurogenic Bladder Disorder, sponsored by University of Gaziantep. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by University of Gaziantep · Observational
Purpose: To evaluate urodynamic parameters predicting the treatment efficacy of onabotulinumtoxin A (onaBoNT-A) in patients with neurogenic lower urinary tract dysfunction (NLUTD).
Methods: Patients with NLUTD who received 200 IU onaBont-A injections at Gaziantep University, Faculty of Medicine, Department of Urology between September 2013 and September 2023 were included in the study. Urodynamic parameters, including cystometric capacity, detrusor pressure (Pdet), and compliance, detrusor leak point pressure (DLPP), phasic or terminal neurogenic overactivity were assessed. Additionally, the correlations between these parameters and treatment outcomes were analyzed.
Changes in the number of pads used per day due to UI were assessed every 3 months during the postoperative period. The time lapsed to return to the pad usage levels before onaBoNT-A injections was recorded as the duration of the benefit.
Preoperative urodynamic data of the patients were compared between groups. Additionally, a subgroup analysis was conducted in patients who benefited from treatment to evaluate the correlation between treatment efficacy, duration of benefit from treatment, and urodynamic parameters.
189 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.
This study's enrollment of 74 is close to the median of 71 across 57 observational studies indexed under Urinary Bladder, Neurogenic.
Browse Urinary Bladder, Neurogenic studies →University of Gaziantep is the lead sponsor of 105 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Neurogenic Lower Urinary Tract Disorder who didn't respond to anticholinergic treatment were the goal population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who respond to the 200 IU Onabotulinum toxin-A injections were allocated to Groups 1
Drug: Botox 200 UNT Injection
Patients who did not respond to the 200 IU Onabotulinum toxin-A injections were allocated to Groups 2
Drug: Botox 200 UNT Injection
Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
Number of patients after onabotulinum a toxin injections who respond to treatment
Time frame: received 200 IU of onaBoNT-A injections for the first time, and followed up regularly for the duration of at least 12 months.
treatment succes duration of patients
The duration of the decrease in the number of pads used was calculated
Time frame: Received 200 IU of onaBoNT-A injections for the first time, and followed up regularly for the duration of at least 12 months.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2013 to primary completion in Sep 2023, 120 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.